Precision Proteomics
for Targeted Breakthroughs
Discover the power of the SomaScan Platform at US HUPO 2025
Precision Proteomics for Targeted Breakthroughs
Join us from February 22–26 in Philadelphia, PA, and visit us at Booth 13 to explore how the SomaScan™ Platform is navigating complex protein landscapes with unparalleled precision and coverage. Don’t miss our Breakfast Symposium on Monday, February 24, Holder text details coming to be more specific here.
Why the SomaScan Assay?
The SomaScan Platform is a scalable and versatile proteomic solution powered by proprietary SOMAmer™ Reagents, enabling high-throughput research in biomarker discovery, drug development and clinical applications.
With the ability to measure 11,000 proteins (half of the human proteome) across diverse sample types, the SomaScan Assay offers:
- Reliable reproducibility: Consistent performance across samples, studies and assay versions, with a low coefficient of variation (CV) of approximately 5%
- Greater sensitivity: Detect both high-abundance (μmol) and low-abundance (fmol) proteins from a single sample, with a 10-fold dynamic range
- Unmatched versatility: Supports discovery, validation and translational studies across various sample types
- Proven scalability: Expanded from 1,000 to 11,000 protein measurements since 2010 without compromising data integrity
BREAKFAST SEMINAR
Leveraging publicly available large-scale proteo-genomics data to identify proteomic drivers of human diseases: A catalog of proteome-phenome-wide associations
Monday, February 24| 7:15–8:15 am
Commonwealth C
Presenter: Satoshi Yoshiji, MD, PhD
- Assistant Professor
- Department of Human Genetics, McGill University
- Visiting Scholar, Broad Institute of MIT and Harvard
Satoshi Yoshiji is an Assistant Professor in the Department of Human Genetics at McGill University and a Visiting Scholar at the Broad Institute of MIT and Harvard. He is a board-certified endocrinologist who trained in genetic epidemiology and proteo-genomics at McGill and the Broad.
His research focuses on leveraging large-scale proteo-genomic and other omics data to understand causal biology and identify potential therapeutic targets for human diseases.